Clarithromycin

Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP

Ranbaxy One of Few Companies to Offer Both Suspension and Tablet Forms PRINCETON, N.J., Oct. 2 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug ...

Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009

...ndependent distributors by an average of 26.0% for clarithromycin Sustained-released tablets, Itopride Hydrochloride...m Hongrui in January 2009. Sales volume for clarithromycin Sustained-released tablets and Baobaole chewable t...009 than in the three months ended March 31, 2008. clarithromycin Sustained-released tablets, Itopride hydrochloride...

China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates

..., and the sales of other products also improved dramatically: year-on-year Alginic Sodium Diester increased by 75.5%, Granisetron increased by 60.47%, clarithromycin increased by 57.4%. The financial operational performance for the 12 months ended December 31, 2008 was clearly improved compared to the 12 mon...

Why does aspirin increase the susceptibility of Helicobacter pylori to antimicrobials?

...ivity of virulence factors of H. pylori . In addition, aspirin increased the susceptibility of H. pylori to antimicrlbials including metronidazole, clarithromycin and amoxicillin. However, the mechanisms remained unknown. A research team led by Prof. Wang from Peking University First Hospital of China address...

An ideal therapy for peptic ulcer disease

...ation became the main objective of therapy, and several treatment regimens were developed. Currently, triple therapy with omeprazole, amoxicillin, and clarithromycin remains the best therapeutic option. Despite its efficacy, 10% to 20% of the patients present with treatment failure, demanding alternative therapeuti...

Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008

... from $18.9 million in the prior year's period. This increase in revenue was mostly due to increased sales of the Company's two most popular products, clarithromycin sustained-release tablets and Itopride Hydrochloride Granules as well as sales of Baobaole chewable tablets, which grew rapidly from the time the prod...

Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook

...t of exchange of 10.5 percent, Kaletra sales increased 20.7 percent internationally. (c) Without the positive impact of exchange of 9.6 percent, clarithromycin sales decreased 10.0 percent internationally. (d) Without the positive impact of exchange of 9.4 percent, Sevorane sales increased 4.4 perc...

GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.

...azole Avoid lovastatin Ketoconazole Erythromycin clarithromycin Telithromycin HIV protease inhibitors Nefazodone Gemfibrozil ...PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of gr...

Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008

...mpared to 71.8% for the prior year period, a slight increase of 0.5%. This increase was due to more efficient manufacturing production by the Company. clarithromycin sustained-release tablets accounted for 65.3% of total revenue during the quarter, with a gross margin approaching 80.0%, and Itopride Hydrochloride g...

Pharma Major Ind-Swift to Enter US, Japan

...ake a foray// into the Japanese drug market. Ind-Swift Laboratories has completed United State Federal Drug Authority (USFDA) inspection for its clarithromycin active pharmaceutical ingredient (API) manufacturing unit, its managing director N.R. Munjal said here Thursday. Clarithromycin is a macrolide a...

Clarithromycin in Medical Technology

Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity

... of the first group, NAB 7061, sensitizes enteric bacteria to other antibiotics. For example, it reduces the minimum inhibitory concentration (MIC) of clarithromycin for ESBL-producing strains of Escherichia coli by a factor of 250-750. NAB 739, the lead compound of the second series, acts directly against enteric ...

Watson Launches Generic Biaxin(R) XL

...n. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today it has launched clarithromycin Extended-Release Tablets, USP in the 500 mg strength. Watson's Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin(R)...

FDA approves MyocondaR IND for MAP in Crohn's Disease

...condaR, the Company's Anti-MAP therapy for the treatment of Crohn's Disease is a combination of three registered anti-mycobacterial drugs - rifabutin, clarithromycin and clofazimine. These three drugs are widely marketed world-wide for the treatment of mycobacterial and other infections. MyocondaR presents these th...

Clarithromycin in Biological News

Scientists discover bacteria that can cause bone infections

...ents. Most mycobacterial infections can be treated with antibiotics such as clarithromycin and rifamycins, but some species are becoming resistant to these antibiotic...terium arosiense can be killed by several antibiotics in the lab, including clarithromycin and rifamycins. However, resistance to fluoroquinolones and isoniazid was o...

UIC scientists discover how some bacteria survive antibiotics

...n feel the presence of erythromycin and activate production of the resistance genes." Erythromycin and newer macrolide antibiotics azithromycin and clarithromycin are often used to treat respiratory tract infections, as well as outbreaks of syphilis, acne and gonorrhea. The drugs can be used by patients allergic...

Clarithromycin in Biological Technology

Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009

...persible Tablets, a drug launched in the first quarter of the Company's fiscal year 2009. Increased revenue was partially offset by decreased sales of clarithromycin Sustained-Release Tablets. Gross profit in the second quarter of the fiscal year 2009 was $25.8 million, an increase of 30.8% from $19.7 millio...

Clarithromycin in Biological Definition

Antibiotic

... Oxazolidinones Linezolid Quinupristin/dalfopristin Polyketides Macrolides Erythromycin Azithromycin clarithromycin Roxithromycin Ketolides Telithromycin Tetracyclines Doxycycline Oxytetracycline Chlortetracycline...